Moderna, Inc. (FRA:0QF)
| Market Cap | 11.52B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,828 |
| Average Volume | 982 |
| Open | 29.31 |
| Previous Close | 28.99 |
| Day's Range | 28.97 - 29.54 |
| 52-Week Range | 19.26 - 43.20 |
| Beta | n/a |
| RSI | 61.18 |
| Earnings Date | Feb 20, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Life-saving therapies are being delayed as research funding dries up | Letter
Dr Carol S Leonard writes that mRNA vaccines are a way forward for those with melanoma, but hopes are dashed by financial cuts This is a critically important editorial ( The Guardian view on mRNA vacc...
Moderna just had its best day since October. Here's what's going on, and what analysts expect
Analysts pointed to an upcoming health care conference and cancer data study release as potential catalysts for Moderna's ongoing rally.
Moderna Stock Fights Back Against Four‑Year Curse With 20% Blastoff And A Golden Cross
Within the first week of 2026, the S&P 500 leaderboard has already delivered a surprise. Moderna Inc (NASDAQ: MRNA) has quietly muscled its way into the top year-to-date performers, up more than 20% i...
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News
MRNA Crosses Above Average Analyst Target
In recent trading, shares of Moderna Inc (Symbol: MRNA) have crossed above the average analyst 12-month target price of $35.30, changing hands for $35.66/share. When a stock reaches the target an anal...
My Top 5 Stocks to Buy in Early 2026
These stocks, ranging from technology to healthcare, could add diversification to your portfolio. Four have proven their earnings strength; the fifth makes a solid recovery story bet.
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?
Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tuesday Sector Leaders: Healthcare, Technology & Communications
In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, higher by 2.1%. Within that group, Moderna Inc (Symbol: MRNA) and Qnity Electronics Inc (Symbol: Q) are two large sto...
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns
Moderna downgraded to neutral at UBS on questions over revenue growth
UBS downgrades Moderna (MRNA) to neutral, citing flat revenue and profitability risks. Read more here.
Notable Tuesday Option Activity: AMSC, MRNA, CORZ
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in American Superconductor Corp. (Symbol: AMSC), where a total volume of 8,128 contra...
S&P 500 Forecast: Healthcare Leads US Stocks Higher—NFP Jobs Report Looms Friday
Healthcare and materials drive gains while energy falls. Moderna surges 7% and Albemarle jumps 12%. Fed’s next move hinges on Friday’s jobs data.
America's new vaccine doctrine for children replaces data with dogma
In just a few weeks, the U.S. went from a “quiet” recalibration of a single vaccine recommendation to a wholesale retreat from the basic architecture of childhood immunization. That shift is being sol...
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissions
Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissions
Moderna (MRNA) Seeks Approval for New Influenza Vaccine
Moderna (MRNA) Seeks Approval for New Influenza Vaccine
Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Older Adults
Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Older Adults
Moderna seeks global approvals for flu shot
Moderna, Inc.: Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an u...
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...
The Guardian view on mRNA vaccines: they are the future – with or without Donald Trump | Editorial
Over the holiday period, the Guardian leader column is looking ahead at the themes of 2026. Today we examine how the White House’s war on vaccines has left the future of a key technology uncertain and...
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Moderna (MRNA) stood at $30.41, denoting a -2.38% move from the preceding trading day.
Notable Tuesday Option Activity: LLY, CRWD, MRNA
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Eli Lilly (Symbol: LLY), where a total volume of 15,152 contracts has been traded thus ...